{"id":"egfr-tki","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Rash/acneiform dermatitis"},{"rate":"30-60","effect":"Diarrhea"},{"rate":"20-40","effect":"Nausea"},{"rate":"20-40","effect":"Fatigue"},{"rate":"1-5","effect":"Interstitial lung disease"}]},"_chembl":{"chemblId":"CHEMBL2107861","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EGFR-TKIs are small-molecule inhibitors that bind to the ATP-binding pocket of EGFR's intracellular tyrosine kinase domain, preventing autophosphorylation and downstream signaling through pathways like MAPK and PI3K/AKT. This mechanism is particularly effective in cancers with EGFR mutations or overexpression, leading to cell cycle arrest and apoptosis.","oneSentence":"EGFR-TKI inhibits epidermal growth factor receptor tyrosine kinase activity to block cancer cell proliferation and survival signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:39.149Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with EGFR mutations"},{"name":"Other EGFR-driven solid tumors"}]},"trialDetails":[{"nctId":"NCT07498595","phase":"EARLY_PHASE1","title":"TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-03-31","conditions":"EGFR-TKI-resistant Non-Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT07413757","phase":"","title":"CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-02","conditions":"Non-Small Cell Lung Cancer","enrollment":590},{"nctId":"NCT05805631","phase":"PHASE2","title":"Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC","status":"RECRUITING","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2024-08-01","conditions":"Carcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis","enrollment":23},{"nctId":"NCT07185997","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations","status":"RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2025-12-17","conditions":"Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer","enrollment":480},{"nctId":"NCT06396065","phase":"PHASE3","title":"Phase III Study of AK112 for NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Summit Therapeutics","startDate":"2023-05-04","conditions":"Non-Squamous Non-small Cell Lung Cancer","enrollment":420},{"nctId":"NCT07100080","phase":"PHASE2, PHASE3","title":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-11-05","conditions":"Non-Small Cell Lung Cancer","enrollment":596},{"nctId":"NCT06671379","phase":"PHASE3","title":"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-11-29","conditions":"Non-small Cell Lung Cancer","enrollment":498},{"nctId":"NCT04077463","phase":"PHASE1","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":701},{"nctId":"NCT07001995","phase":"PHASE2","title":"Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression","status":"NOT_YET_RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2026-05-01","conditions":"Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC","enrollment":30},{"nctId":"NCT07230691","phase":"","title":"A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-12-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":380},{"nctId":"NCT05364073","phase":"PHASE1","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2022-06-30","conditions":"Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer","enrollment":160},{"nctId":"NCT07155187","phase":"PHASE2, PHASE3","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-12-10","conditions":"Non-Small Cell Lung Cancer","enrollment":430},{"nctId":"NCT07461727","phase":"PHASE1","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-10","conditions":"Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases","enrollment":15},{"nctId":"NCT05636267","phase":"PHASE1, PHASE2","title":"Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients","status":"TERMINATED","sponsor":"Akeso","startDate":"2023-02-10","conditions":"NSCLC","enrollment":59},{"nctId":"NCT02716116","phase":"PHASE1, PHASE2","title":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2016-06-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":334},{"nctId":"NCT06830694","phase":"PHASE2","title":"Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment","status":"RECRUITING","sponsor":"Se-Hoon Lee","startDate":"2025-05-13","conditions":"Small Cell Carcinoma of Lung","enrollment":50},{"nctId":"NCT06043817","phase":"PHASE1, PHASE2","title":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations","status":"RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2023-09-26","conditions":"Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation","enrollment":251},{"nctId":"NCT03042221","phase":"","title":"Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2016-05-10","conditions":"Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation","enrollment":100},{"nctId":"NCT04868877","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merus B.V.","startDate":"2021-04-28","conditions":"Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma","enrollment":194},{"nctId":"NCT06741085","phase":"PHASE2","title":"A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-12-13","conditions":"Non Small Cell Lung Cancer Metastatic","enrollment":56},{"nctId":"NCT07416058","phase":"PHASE2","title":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2026-01-31","conditions":"Lung Adenocarcinoma","enrollment":61},{"nctId":"NCT07414927","phase":"PHASE1, PHASE2","title":"A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Best-Link Bioscience, LLC","startDate":"2026-03-27","conditions":"Small Cell Carcinoma of Lung","enrollment":48},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT07398599","phase":"NA","title":"Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2026-02-15","conditions":"Leptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06706076","phase":"PHASE1, PHASE2","title":"A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","status":"RECRUITING","sponsor":"BlossomHill Therapeutics","startDate":"2025-01-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":266},{"nctId":"NCT03133546","phase":"PHASE2","title":"Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2017-05-31","conditions":"Non Small Cell Lung Cancer Metastatic","enrollment":155},{"nctId":"NCT07229339","phase":"PHASE2","title":"Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2027-06-01","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":16},{"nctId":"NCT04184921","phase":"PHASE2","title":"Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients","status":"COMPLETED","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2019-01-01","conditions":"Lung Cancer Non-small Cell Stage IV","enrollment":216},{"nctId":"NCT04626635","phase":"PHASE1, PHASE2","title":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-12-21","conditions":"Advanced Solid Tumors","enrollment":933},{"nctId":"NCT02143466","phase":"PHASE1","title":"AZD9291 in Combination With Ascending Doses of Novel Therapeutics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-08-05","conditions":"Advanced Non Small Cell Lung Cancer","enrollment":344},{"nctId":"NCT05816252","phase":"PHASE2","title":"A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Klus Pharma Inc.","startDate":"2023-04-19","conditions":"Non-small Cell Lung Cancer","enrollment":356},{"nctId":"NCT05601973","phase":"PHASE2","title":"Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2023-03-27","conditions":"Non Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT04486833","phase":"PHASE1, PHASE2","title":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","status":"RECRUITING","sponsor":"Genprex, Inc.","startDate":"2021-09-03","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":158},{"nctId":"NCT02609776","phase":"PHASE1","title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-24","conditions":"Non-Small-Cell Lung Cancer","enrollment":751},{"nctId":"NCT07343479","phase":"PHASE2","title":"Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2026-05-01","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations, Brain Metastasis","enrollment":45},{"nctId":"NCT05845671","phase":"PHASE1, PHASE2","title":"Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-07-17","conditions":"Lung Cancer, Non Small Cell Lung Cancer","enrollment":12},{"nctId":"NCT07338396","phase":"","title":"A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2026-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":3000},{"nctId":"NCT02296125","phase":"PHASE3","title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-03","conditions":"Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer","enrollment":674},{"nctId":"NCT07310589","phase":"NA","title":"Effects of a Visual Interactive LINE Chatbot on Self-Management of EGFR-TKI Related Side Effects in Patients With Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-01-01","conditions":"Non-Small Cell Lung Cancer","enrollment":178},{"nctId":"NCT02511106","phase":"PHASE3","title":"AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-10-21","conditions":"Stage IB-IIIA Non-small Cell Lung Carcinoma","enrollment":682},{"nctId":"NCT05463224","phase":"PHASE2","title":"Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Se-Hoon Lee","startDate":"2023-01-02","conditions":"NSCLC","enrollment":150},{"nctId":"NCT02314364","phase":"PHASE2","title":"A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-12","conditions":"Non-small Cell Lung Cancer Metastatic, Targetable Oncogenes (EGFR, ALK, ROS1)","enrollment":27},{"nctId":"NCT07285148","phase":"PHASE1, PHASE2","title":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","startDate":"2026-06","conditions":"Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer","enrollment":253},{"nctId":"NCT05256290","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Black Diamond Therapeutics, Inc.","startDate":"2022-03-31","conditions":"Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma","enrollment":200},{"nctId":"NCT07271446","phase":"PHASE1","title":"An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer","status":"COMPLETED","sponsor":"Precision Biotech Taiwan Corp.","startDate":"2018-09-01","conditions":"Non-small Cell Lung Cancer","enrollment":8},{"nctId":"NCT05870319","phase":"PHASE3","title":"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2023-06-26","conditions":"Non-small Cell Lung Cancer","enrollment":376},{"nctId":"NCT07267247","phase":"","title":"Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2022-06-01","conditions":"Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), Drug-Related Side Effects and Adverse Reactions (MeSH Term), Egfr Tyrosine Kinase Inhibitor","enrollment":100},{"nctId":"NCT05370469","phase":"NA","title":"Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2022-08-25","conditions":"Lung Cancer, EGFR Gene Mutation, EGFR","enrollment":30},{"nctId":"NCT06652048","phase":"PHASE2","title":"High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI","status":"RECRUITING","sponsor":"Jialei Wang","startDate":"2024-10-01","conditions":"Non-Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT02197234","phase":"PHASE1","title":"Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-22","conditions":"Non Small Cell Lung Cancer","enrollment":52},{"nctId":"NCT05456256","phase":"PHASE2","title":"A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma","status":"RECRUITING","sponsor":"Lantern Pharma Inc.","startDate":"2023-03-01","conditions":"Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung","enrollment":90},{"nctId":"NCT02157883","phase":"PHASE1","title":"Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-06","conditions":"Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer","enrollment":39},{"nctId":"NCT06382116","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-05-22","conditions":"Non-small Cell Lung Cancer","enrollment":432},{"nctId":"NCT06927986","phase":"PHASE3","title":"Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）","status":"RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-03-30","conditions":"EGFR-mutated Locally Advanced or Metastatic NSCLC","enrollment":380},{"nctId":"NCT03909334","phase":"PHASE2","title":"Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiuning Le","startDate":"2019-07-25","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer","enrollment":160},{"nctId":"NCT04001777","phase":"PHASE1","title":"A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-07-04","conditions":"EGFR Positive Non-small Cell Lung Cancer","enrollment":80},{"nctId":"NCT07181499","phase":"PHASE2","title":"Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI","status":"RECRUITING","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2025-09","conditions":"NSCLC, Adjuvant Drug Therapy, EGFR","enrollment":28},{"nctId":"NCT07197008","phase":"PHASE2","title":"Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Li-kun Chen","startDate":"2025-10-01","conditions":"Lung Cancer","enrollment":50},{"nctId":"NCT06304441","phase":"NA","title":"Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer","status":"RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2024-04-18","conditions":"Leptomeningeal Metastasis","enrollment":100},{"nctId":"NCT05020769","phase":"PHASE2, PHASE3","title":"SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2022-01-06","conditions":"Non-small Cell Lung Cancer","enrollment":14},{"nctId":"NCT07193160","phase":"PHASE2","title":"Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11-01","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":45},{"nctId":"NCT06020066","phase":"PHASE2","title":"SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2023-08-10","conditions":"Brain Metastases, Non-small Cell Lung Cancer","enrollment":202},{"nctId":"NCT03653546","phase":"PHASE2, PHASE3","title":"First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases","status":"COMPLETED","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2018-10-29","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases","enrollment":492},{"nctId":"NCT05236946","phase":"PHASE3","title":"Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT","status":"RECRUITING","sponsor":"Tata Memorial Hospital","startDate":"2020-11-10","conditions":"Asymptomatic Brain Metastases, Driver Mutation Positive Non-small Cell Lung Cancer","enrollment":190},{"nctId":"NCT07152782","phase":"PHASE2","title":"T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11","conditions":"Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer","enrollment":202},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT07109531","phase":"PHASE3","title":"ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","startDate":"2025-08-31","conditions":"Locally Advanced or Metastatic NSCLC","enrollment":286},{"nctId":"NCT05517330","phase":"PHASE2","title":"Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2022-09-19","conditions":"Head and Neck Cancer","enrollment":23},{"nctId":"NCT05078931","phase":"PHASE2","title":"A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2021-10-27","conditions":"NSCLC","enrollment":35},{"nctId":"NCT07087223","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-04-08","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":42},{"nctId":"NCT06062823","phase":"PHASE2","title":"Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2024-03-25","conditions":"NSCLC","enrollment":35},{"nctId":"NCT06161558","phase":"PHASE1","title":"Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2025-07-15","conditions":"Neoplasms","enrollment":""},{"nctId":"NCT06953843","phase":"PHASE2","title":"Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases","status":"RECRUITING","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2025-07-09","conditions":"NSCLC Stage IV Without EGFR/ALK Mutation","enrollment":366},{"nctId":"NCT04591002","phase":"PHASE2","title":"Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2022-07-26","conditions":"Lung Cancer","enrollment":43},{"nctId":"NCT07036016","phase":"","title":"Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2015-01-01","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":67818},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT04027647","phase":"PHASE2","title":"Phase 2 Study of Dacomitinib in NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2019-09-11","conditions":"NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV","enrollment":118},{"nctId":"NCT03292133","phase":"PHASE2","title":"A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2017-10-31","conditions":"Lung Cancer","enrollment":11},{"nctId":"NCT06924398","phase":"PHASE2","title":"Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-20","conditions":"Lung Cancer (NSCLC)","enrollment":32},{"nctId":"NCT04820023","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment","status":"TERMINATED","sponsor":"Bridge Biotherapeutics, Inc.","startDate":"2021-04-02","conditions":"NSCLC","enrollment":45},{"nctId":"NCT05516589","phase":"PHASE2","title":"Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2022-09-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT06343064","phase":"PHASE1, PHASE2","title":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI","status":"RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2023-06-13","conditions":"Non-Small-Cell Lung Cancer","enrollment":156},{"nctId":"NCT06970782","phase":"PHASE3","title":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure","status":"NOT_YET_RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2025-05-15","conditions":"Non-Small-Cell Lung Cancer","enrollment":278},{"nctId":"NCT05852990","phase":"PHASE3","title":"Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC","status":"RECRUITING","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2022-03-01","conditions":"Non-Small Cell Lung Cancer With EGFR Mutation","enrollment":28},{"nctId":"NCT05994131","phase":"PHASE1, PHASE2","title":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC","status":"RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2023-07-13","conditions":"NSCLC","enrollment":110},{"nctId":"NCT04075396","phase":"PHASE1, PHASE2","title":"A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-10-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":29},{"nctId":"NCT05920135","phase":"PHASE1, PHASE2","title":"First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bridge Biotherapeutics, Inc.","startDate":"2023-09-11","conditions":"EGFR Mutant Advanced Non-Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT06613633","phase":"","title":"Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC","status":"COMPLETED","sponsor":"Fudan University","startDate":"2018-09-01","conditions":"Third-generation TKI, NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":4000},{"nctId":"NCT01853826","phase":"PHASE3","title":"An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-07-17","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":481},{"nctId":"NCT05868226","phase":"PHASE1","title":"PRE-I-SPY Phase I/Ib Oncology Platform Program","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2023-02-15","conditions":"HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer","enrollment":124},{"nctId":"NCT05756972","phase":"PHASE2","title":"A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biotheus Inc.","startDate":"2023-06-26","conditions":"NSCLC","enrollment":64},{"nctId":"NCT06908772","phase":"PHASE2, PHASE3","title":"Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-04-01","conditions":"Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression","enrollment":390},{"nctId":"NCT02717221","phase":"NA","title":"In Vivo EGFR Molecular Classification and Treatment Response","status":"COMPLETED","sponsor":"Harbin Medical University","startDate":"2014-11","conditions":"Molecular Imaging","enrollment":102},{"nctId":"NCT05298176","phase":"PHASE2","title":"Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2022-01-04","conditions":"Non-Small Cell Lung Cancer","enrollment":5},{"nctId":"NCT02489903","phase":"PHASE2","title":"RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)","status":"COMPLETED","sponsor":"EpicentRx, Inc.","startDate":"2015-06","conditions":"Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors","enrollment":139},{"nctId":"NCT04777084","phase":"PHASE2","title":"The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2021-08-01","conditions":"Non-Small Cell Lung Cancer","enrollment":120},{"nctId":"NCT03543683","phase":"PHASE2","title":"Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC","status":"COMPLETED","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2018-01-01","conditions":"Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, EGFR T790M","enrollment":115},{"nctId":"NCT02424617","phase":"PHASE1, PHASE2","title":"A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BerGenBio ASA","startDate":"2015-04-19","conditions":"Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT05215548","phase":"PHASE2","title":"Primary Tumor Resection With EGFR TKI for Stage IV NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-09-27","conditions":"NSCLC Stage IV","enrollment":100},{"nctId":"NCT06813079","phase":"PHASE2","title":"Using Tumor Models to Determine Treatments","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-02-17","conditions":"Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial Tumor","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4879,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Imatinib、Gefitinib or Erlotinib","Gefitinib/Tarceva/Icotinib","gefitinib","Gefitinib/Erlotinib/Icotinib","Erlotinib:150 mg oral, once a day,Tarceva"],"phase":"phase_3","status":"active","brandName":"EGFR-TKI","genericName":"EGFR-TKI","companyName":"Sichuan Cancer Hospital and Research Institute","companyId":"sichuan-cancer-hospital-and-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EGFR-TKI is used to treat Non-Small Cell Lung Cancer (NSCLC) and has been studied in combination with other treatments such as chemotherapy and other medications like Gefitinib. The mechanism of EGFR-TKI involves targeting the epidermal growth factor receptor (EGFR) to inhibit cancer cell growth.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2018-09-27T00:00:00.000Z","mah":"Mylan Pharmaceuticals Limited","brand_name_local":"Gefitinib Mylan","application_number":"EMEA/H/C/004826"}],"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}